All In Biotech

Drug Trial Radar · NCT02833350

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)

Last checked: Nov 19, 2026Latest source record: Jun 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 578 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

578

Actual

Start

Sep 9, 2016

Primary completion

Jul 2, 2018

Study completion Jul 2, 2018

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).

Conditions

  • Rheumatoid Arthritis

Interventions

  • GDC-0853Drug

    Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

  • AdalimumabDrug

    Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.

  • Folic AcidDrug

    Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

  • MTXDrug

    Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).

  • PlaceboDrug

    Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)Time frame: Day 84
  2. Percentage of Participants With Adverse EventsTime frame: Day 1 up to 8 weeks after last dose (up to Week 20)

Locations

150 sites in 11 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group; Llc, Central

    Anniston, Alabama

  • Arizona Arthritis & Rheumatology Associates, P.C.

    Glendale, Arizona

  • Medvin Clinical Research

    Covina, California

  • TriWest Research Associates, LLC

    El Cajon, California

  • Saint Jude Heritage Medical Grp

    Fullerton, California

  • Stanford University School of Medicine

    Stanford, California

  • RASF-Clinical Research Center

    Boca Raton, Florida

  • ZASA Clinical Research

    Boynton Beach, Florida

  • Clinical Research of West Florida

    Clearwater, Florida

  • InVentiv Health

    Miami, Florida

  • Omega Research Consultants

    Orlando, Florida

  • McIlwain Medical Group

    Tampa, Florida

  • Institute of Arthritis Research

    Idaho Falls, Idaho

  • Advanced Clinical Research

    Meridian, Idaho

  • Medication Management

    Greensboro, North Carolina

  • Oregon Health and Science University

    Portland, Oregon

  • Clinical Research Center of Reading

    Wyomissing, Pennsylvania

  • Metroplex Clinical Research

    Dallas, Texas

  • Baylor Research Inst.

    Dallas, Texas

  • Accurate Clinical Management - VO

    Houston, Texas

  • Accurate Clinical Research

    Houston, Texas

  • Crossroads Clinical Research, LLC

    Victoria, Texas

  • Danville Orthopedic Clinic, Inc.; Research Department

    Danville, Virginia

  • Instituto de Investigaciones Clinicas-Mar del Plata

    Buenos Aires, Argentina

  • Organizacion Medica de Investigacion

    Buenos Aires, Argentina

  • Hospital Italiano

    Buenos Aires, Argentina

  • APRILLUS

    Buenos Aires, Argentina

  • Instituto centenario

    Buenos Aires, Argentina

  • Centro de Investigacion en Enfermedades Reumaticas CIER

    Ciudad Autonoma Buenos Aires, Argentina

  • Expertia S.A- Mautalen Salud e Investigación

    Ciudad Autonoma Buenos Aires, Argentina

  • CCBR - Buenos Aires - AR; AxisMed SRL

    Ciudad Autonoma Buenos Aires, Argentina

  • ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas

    Córdoba, Argentina

  • Hospital Italiano de La Plata

    La Plata, Argentina

  • Centro de Investigaciones Medicas Mar Del Plata

    Mar del Plata, Argentina

  • Instituto de Investigaciones Clínicas Quilmes

    Quilmes, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica

    San Juan, Argentina

  • Centro Medico Privado de Reumatologia; Reumathology

    San Miguel, Argentina

  • CIP - Centro Internacional de Pesquisa; Pesquisa Clinica

    Goiânia, Goiás, Brazil

  • Centro Mineiro de Pesquisa - CMIP

    Juiz de Fora, Minas Gerais, Brazil

  • Edumed - Educação e Saúde SA

    Curitiba, Paraná, Brazil

Showing 40 of 150 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.